Results 71 to 80 of about 44,177 (299)

The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease [PDF]

open access: yes, 2018
Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective immunotherapeutic approach for various hematologic and immunologic ailments. Despite the beneficial impact of allo-HCT, its adverse effects cause severe health concerns.
Sandeep Kumar   +2 more
core   +1 more source

[Control of graft-vs-host disease].

open access: yes[Rinsho ketsueki] The Japanese journal of clinical hematology, 1990
Considering the merit and demerit of GVHD in leukemia patients following allogeneic BMT, our strategies for GVHD are as follows; (1) a mild prevention, (2) a treatment to control the severity, if occurred, and (3) an induction of GVHD in recipients who did not develop GVHD. We reported the results of recent trials in prevention, treatment and induction
openaire   +2 more sources

HNRNPD Induces Radioresistance in Nasopharyngeal Carcinoma by Sequestering GRAMD4 mRNA in Stress Granules

open access: yesAdvanced Science, EarlyView.
HNRNPD promotes radioresistance in nasopharyngeal carcinoma by enhancing stress granule assembly and sequestering GRAMD4 mRNA. This suppresses GRAMD4 translation and inhibits mitochondrial apoptosis. Targeting the integrated stress response with ISRIB restores GRAMD4 expression and sensitizes tumors to radiotherapy, revealing a translational control ...
Yingzi Li   +13 more
wiley   +1 more source

Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease

open access: yesFrontiers in Immunology, 2018
Acute graft-vs.-host disease (aGVHD) is a frequent complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), accounting for substantial morbidity and mortality associated with this treatment modality.
Nina C. Zitzer   +3 more
doaj   +1 more source

Donor mesenchymal stem cells trigger chronic graft-versus-host disease following minor antigen-mismatched bone marrow transplantation

open access: yes, 2012
Chronic graft-versus-host disease (cGVHD) is a complication after minor antigen mismatched bone marrow transplantation (BMT) characterized by an autoimmune-type reaction in various organs.
Yumi Matsuzaki   +12 more
core  

Tumor‐Derived Exosomes Deliver Membrane‐Bound Fgl2 to Activate FcγRIIB‐Mediated Immunosuppression in Myeloid‐Derived Suppressor Cells

open access: yesAdvanced Science, EarlyView.
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin   +12 more
wiley   +1 more source

Lipoic Acid‐Intervened Decellularized Stem Cell Spheroid‐Based Injectable Granular Gel for Diabetic Tissue Regeneration

open access: yesAdvanced Science, EarlyView.
ABSTRACT Advancements in tissue engineering have revolutionized therapeutic paradigms for diabetic tissue defects; however, the lack of applicable scaffold containing various bioactive substance aggregates remained a critical bottleneck hindering satisfactory repair effect.
Tao Wang   +8 more
wiley   +1 more source

Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects

open access: yesOncoImmunology, 2017
The demethylating agent 5-azacytidine (AZA) has proven its efficacy in the treatment of myelodysplastic syndrome and acute myeloid leukemia. In addition, AZA can demethylate FOXP3 intron 1 (FOXP3i1) leading to the generation of regulatory T cells (Treg).
Grégory Ehx   +11 more
doaj   +1 more source

The IL-12 Cytokine and Receptor Family in Graft-vs.-Host Disease

open access: yesFrontiers in Immunology, 2019
Allogeneic hematopoietic cell transplantation (allo-HCT) is performed with curative intent for high- risk blood cancers and bone marrow failure syndromes; yet the development of acute and chronic graft-vs.-host disease (GVHD) remain preeminent causes of ...
David Bastian   +4 more
doaj   +1 more source

Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin

open access: yes, 1999
465-469Our unit performed transplantations on 21 classes II and III thalassaemic patients [class II patients had either hepatomegaly or portal fibrosis and class III patients had both]. We used busulfan [15 mg/kg] and cyclophosphamide [200 mg/kg].
Khojasteh, H.N.
core  

Home - About - Disclaimer - Privacy